Stockscreener 앱 받기
2.97
1.37%
0.04
Adverum Biotechnologies Inc 주식(ADVM)의 최신 뉴스
Chartists Watching For Breakout in Adverum Biotechnologies Inc.July 2025 Action & Daily Stock Trend Watchlist - newsyoung.net
Global Ophthalmology Drugs Market to Reach USD 26.28 Billion by 2030 | MarketsandMarkets™ - GlobeNewswire Inc.
Real time alert setup for Adverum Biotechnologies Inc. performanceStock Surge & Reliable Momentum Entry Alerts - Newser
Full technical analysis of Adverum Biotechnologies Inc. stockJuly 2025 Selloffs & Free High Return Stock Watch Alerts - Newser
Technical analysis overview for Adverum Biotechnologies Inc. stockWeekly Stock Summary & Smart Money Movement Alerts - Newser
Reversal indicators forming on Adverum Biotechnologies Inc. stock2025 Volatility Report & Fast Entry High Yield Tips - Newser
Chardan Capital Keeps Buy Rating for ADVM with $33 Price Target - AInvest
Adverum Biotechnologies (NASDAQ:ADVM) Receives “Buy” Rating from Chardan Capital - Defense World
What makes Adverum Biotechnologies Inc. stock price move sharply2025 Earnings Surprises & Stock Portfolio Risk Control - Newser
How to build a dashboard for Adverum Biotechnologies Inc. stockGDP Growth & Verified Trade Idea Suggestions - Newser
Chardan Capital Keeps Buy Rating on Adverum, Raises PT to $33 - AInvest
Using data tools to time your Adverum Biotechnologies Inc. exit2025 Geopolitical Influence & Low Risk Entry Point Tips - Newser
Adverum Biotechnologies shares rise 6.88% premarket after reporting a loss of $49.2 million in Q2 2025. - AInvest
Adverum Biotechnologies: Q2 Earnings Snapshot - Greenwich Time
Promising Outlook for Adverum Biotechnologies’ Ixo-vec in Wet AMD Treatment: Buy Rating Affirmed - TipRanks
How high can Adverum Biotechnologies Inc. stock price go in 20252025 Volatility Report & Long-Term Growth Stock Strategies - Newser
Adverum Biotechnologies Faces Financial Hurdles Amid Gene Therapy Development - AInvest
Adverum Biotechnologies Faces Financial Challenges Amid Gene Therapy Development - TipRanks
Adverum Biotechnologies Reports Second Quarter 2025 Financial Results and Provides Pipeline Highlights - GlobeNewswire
Adverum Biotechnologies shares fall 8.91% after-hours after reporting a larger-than-expected Q2 loss. - AInvest
Adverum Biotechnologies shares rise 4.86% after-hours despite reporting a $49.2 million loss in Q2. - AInvest
Adverum Biotechnologies Q2: ARTEMIS Phase 3 enrollment exceeds expectations. - AInvest
Adverum Biotechnologies Q2 GAAP EPS Misses Expectations, Cash Holdings Down to $44.4M - AInvest
Adverum Biotechnologies Reports Q2 2025 Financial Results, Exceeds ARTEMIS Enrollment Expectations, Announces $10M Private Placement with Frazier Life Sciences. - AInvest
Adverum Biotechnologies, Inc. SEC 10-Q Report - TradingView
Adverum Biotechnologies reports Q2 EPS ($2.34), consensus ($2.28) - TipRanks
Adverum Biotechnologies Q2: ARTEMIS Phase 3 Enrollment Exceeds Expectations, $10mln Private Placement - AInvest
Adverum's One-and-Done Eye Treatment Attracts Record Trial Enrollment as 50% of Specialists Back Gene Therapy - Stock Titan
Technical signs of recovery in Adverum Biotechnologies Inc.3-Year Equity Summary With Setup Insights - Newser
Published on: 2025-08-11 03:29:27 - Newser
Is Adverum Biotechnologies Inc. stock bottoming outReal Trader Watchlist with Entry Targets - Newser
What to do if you’re stuck in Adverum Biotechnologies Inc.High Confidence Strategy with Trend Alignment - Newser
Adverum Biotechnologies Inc. stock prediction for this weekChart Driven Opportunity Scanner with Alerts - Newser
Is Adverum Biotechnologies Inc. a candidate for recovery playMarket Opportunity Tracker for Swing Traders - Newser
Adverum Biotechnologies Inc expected to post a loss of $2.25 a shareEarnings Preview - TradingView
Adverum Biotechnologies shares fall 2.38% intraday after executives to participate in H.C. Wainwright 5th Annual Ophthalmology Virtual Conference. - AInvest
Adverum Biotechnologies to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference - GlobeNewswire
Adverum Leadership to Share Latest Ophthalmology Insights at H.C. Wainwright Conference - Stock Titan
0.94%
1.72%
자본화:
|
볼륨(24시간):